CD8A and neoplasm: Using ex vivo and in vitro models, the findings from this study demonstrated that the post-FLOT and post-CROSS chemotherapy tumour cell secretome and tumour biopsy secretome significantly increased the frequencies of effector memory and terminally differentiated effector memory CD8+ T cell phenotypes.